Original expectations of the Hancock valve and 20 years of clinical reality.
The standard (glutaraldehyde-preserved) Hancock porcine bioprosthesis was introduced into clinical practice in order to provide surgeons with a cardiac valve substitute which would be nonthrombogenic and therefore would not require anticoagulation, and would be durable, anatomically suitable, and noiseless. In the present report we have reviewed our long-term experience with Hancock porcine valve recipients in order to verify the original expectations of this bioprosthesis have been met.
Bortolotti
U
U
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.
Milano
A
A
Thiene
G
G
Mazzucco
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001705:Bioprosthesis / Q000592:standards*; D002648:Child; D005500:Follow-Up Studies; D005976:Glutaral / Q000627:therapeutic use; D006350:Heart Valve Prosthesis / Q000592:standards*; D006785:Hospitals, University; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D011475:Prosthesis Failure; D016459:Prosthesis-Related Infections / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D015996:Survival Rate; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D014021:Tissue Preservation / Q000379:methods
D005976:Glutaral